Methods and compositions for treating pain
View Patent ↗Methods and compositions for treating pain are disclosed. The compositions are based on dry powders comprising microparticles of diketopiperazines and an analgesic active agent. The analgesic in the compositions comprises one or more peptide analgesics or derivatives thereof, which are administered to a subject using a pulmonary inhalation drug delivery system comprising a dry powder inhaler and the analgesic composition. The present compositions produce fewer side effects associated with current opioid therapy.
1. An inhalable, analgesic composition comprising microparticles of a diketopiperazine and a peptide comprising less than 20 amino acids; wherein said composition is effective at relieving pain, wherein the peptide is an opioid receptor agonist.
2. The inhalable analgesic composition of claim 1 , wherein the peptide comprises at least three amino acids independently selected from arginine, phenylalanine, leucine, isoleucine, norleucine, tyrosine, serine, proline, and tryptophan.
3. The inhalable analgesic composition of claim 2 , wherein the peptide is an amino acid sequence of from three to eight amino acids in length.
4. The inhalable analgesic composition of claim 3 , wherein the peptide is a four amino acid sequence and the composition is for pulmonary administration.
5. The inhalable analgesic composition of claim 3 , wherein the peptide comprises: (D)Phe-(D)Phe-(D)Ile-(D)Arg-NH 2 (SEQ ID NO: 1) or (D)Phe-(D)Phe-(D)Nle-(D)Arg-NH 2 (SEQ ID NO: 2).
6. The inhalable analgesic composition of claim 1 , wherein the peptide binds to a μ opioid receptor, a δ opioid receptor, or a κ opioid receptor, or combinations of receptors thereof, on cells in the central or peripheral nervous systems.
7. The inhalable analgesic composition of claim 1 , wherein the peptide is a κ opioid receptor agonist.
8. The inhalable analgesic composition of claim 1 , wherein the composition comprises a dry powder, and the peptide comprises at least 0.25% of the weight of the composition.
9. The inhalable analgesic composition of claim 1 , wherein the composition comprises a dry powder for inhalation and comprises microparticles having a volumetric mean geometric diameter less than 8 μm in diameter.
10. The inhalable analgesic composition of claim 1 , wherein the diketopiperazine is an N-substituted-3,6-aminoalkyl-2,5-diketopiperazine.
11. The inhalable analgesic composition of claim 10 , wherein the diketopiperazine is 3,6-bis(N-fumaryl-4-aminobutyl)-2,5-diketopiperazine, or 3,6-bis(N-fumaryl-4-aminobutyl)-2,5-diketopiperazine disodium salt.
12. The inhalable analgesic composition of claim 1 , wherein the diketopiperazine is 3,6-bis(N-X-4-aminobutyl)-2,5-diketopiperazine, wherein X is fumaryl, succinyl, glutaryl, maleyl, malonyl, oxalyl, or a pharmaceutically acceptable salt thereof.
13. The inhalable analgesic composition of claim 1 , further comprising one or more pharmaceutical carrier or excipients selected from amino acids, sugars and surfactants.
14. The inhalable analgesic composition of claim 13 , wherein the amino acids comprise at least one of leucine, isoleucine, glycine and methionine.
15. The inhalable analgesic composition of claim 13 , wherein the sugars comprise at least one of mannitol, lactose, trehalose and raffinose.
16. A dry powder for pulmonary inhalation comprising the inhalable analgesic composition of claim 11 .
17. A method for treating pain, comprising administering to a subject in need of treatment a therapeutically effective amount of an inhalable analgesic composition comprising microparticles of a diketopiperazine and a peptide comprising less than 20 amino acids using a dry powder drug delivery system, wherein the peptide is an opioid receptor agonist.
18. The method of claim 17 , wherein the dry powder drug delivery system comprises a dry powder inhaler configured with a container to hold said inhalable analgesic composition in a containment configuration and in a dosing configuration.
19. The method of claim 17 , wherein the inhalable analgesic composition comprises a dry powder comprising a peptide that binds to an opiate receptor.
20. The method of claim 19 , wherein the diketopiperazine is 3,6-bis(N-fumaryl-4-aminobutyl)-2,5-diketopiperazine, or 3,6-bis(N-fumaryl-4-aminobutyl)-2,5-diketopiperazine dosodium salt.
21. The method of claim 19 , wherein the peptide comprises: (D)Phe-(D)Phe-(D)Ile-(D)Arg-NH 2 (SEQ ID NO: 1) or (D)Phe-(D)Phe-(D)Nle-(D)Arg-NH 2 (SEQ ID NO: 2).
22. The method of claim 19 , wherein the peptide binds to a μ opioid receptor, a δ opioid receptor, or a κ opioid receptor, or combinations of receptors thereof, of cells in the central or peripheral nervous systems.
23. An inhalable analgesic composition comprising 3,6-bis(N-X-4-aminobutyl)-2,5-diketopiperazine wherein X is fumaryl or a pharmaceutically acceptable salt thereof, and a synthetic peptide having the amino acid sequence: (D)Phe-(D)-Phe-(D)Ile-(D)Arg-NH 2 (SEQ ID NO: 1) or (D)Phe-(D)Phe-(D)Nle-(D)Arg-NH 2 (SEQ ID NO: 2).
24. The inhalable analgesic composition of claim 23 , further comprising one or more amino acids selected from the group consisting of leucine, isoleucine, glycine and methionine.
25. The inhalable analgesic composition of claim 23 , wherein the peptide binds to a κ opioid receptor on cells in the central or peripheral nervous systems.